TVM Unveils AI-Centric Sessions for Biopharma at BIO-Europe 2024

TVM Capital Life Science, an international venture capital firm, will host a series of sessions at BIO-Europe 2024 in Stockholm, focusing on artificial intelligence (AI) in biopharma. Set for November 5, the event aims to examine AI's growing role in drug discovery, diagnostics, and patient care.

TVM's Managing Partner, Dr. Hubert Birner, highlights AI's transformational impact on healthcare. The gathering will feature experts discussing both advancements and challenges. Notably, Verena Schustereder from Google Europe will keynote, exploring AI's influence on biopharma efficiency and innovation.

Two main sessions, "AI for Drug Discovery" and "AI for Diagnosis," will address the speeding up of drug development and enhancement of diagnostic accuracy, respectively. Industry leaders will provide insights and real-world case studies, illustrating AI's practical applications in biopharma.